Concurrent Cardioversion of Atrial Fibrillation during ICD Shock Testing

Pacing Clin Electrophysiol. 2015 Jul;38(7):864-9. doi: 10.1111/pace.12644. Epub 2015 May 6.

Abstract

Background: Many patients receiving an implantable cardioverter-defibrillator (ICD) also have atrial fibrillation (AF). Shock testing during ICD implantation carries a potential risk of cardioversion to sinus rhythm (SR) and thrombembolic events. We aimed to analyze the recurrence of AF after cardioversion to SR during ICD shock testing.

Methods: A total of 555 consecutive patients referred to a tertiary hospital in Switzerland for ICD implantation or generator exchange between 02/2002 and 03/2010 were screened for AF. Fifty-seven patients who were in AF at the time of ICD shock testing were included.

Results: Forty-four patients (77%) were successfully cardioverted from AF to SR. Type of AF (persistent, not permanent 64 vs 31% of cardioverted patients) was the only predictor. Thirty-nine patients (89%) experienced a recurrence of AF/atrial flutter after a median of 54 days (interquartile range 35-251 days). The only predictor for recurrence of AF was previous AF declared as permanent. No ischemic stroke occurred during hospitalization for the procedure.

Conclusions: For patients in AF undergoing shock testing at the time of ICD implant, there is a high chance of cardioversion from AF to SR, but there is also a high risk of early recurrence. Decisions regarding long-term anticoagulation should not be based on the heart rhythm immediately following shock testing.

Keywords: atrial fibrillation; cardioversion; implantable cardioverter-defibrillator; shock testing; sinus rhythm.

Publication types

  • Clinical Trial

MeSH terms

  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / etiology*
  • Atrial Fibrillation / prevention & control*
  • Defibrillators, Implantable / adverse effects*
  • Equipment Failure Analysis
  • Female
  • Heart Failure / complications*
  • Heart Failure / diagnosis
  • Heart Failure / prevention & control*
  • Humans
  • Male
  • Recurrence
  • Treatment Outcome